On September 6, 2022 Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, reported that the Company will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid conference (Press release, Protalix, SEP 6, 2022, https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301618133.html [SID1234619110]). The conference is being held on September 12-14, 2022 at the Lotte New York Palace Hotel in New York City. Virtual participation will also be available.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dror Bashan, the Company’s President and Chief Executive Officer, will provide a corporate overview at the conference. A webcast of the presentation will be available commencing on Monday, September 12, 2022 at 7:00 AM, Eastern time, and will be archived.

Webcast Details:

The conference will be webcast live from the Company’s website and will be available via the following links:

The Company’s management will participate in one-on-one meetings with investors who are registered to attend the conference. If you are an institutional investor and would like to attend the Company’s presentation, registration for the conference is available at View Source Once your registration is confirmed, you will be prompted to log onto the conference website to request a one-on-one meeting with the Company.